[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
about
Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticalsSynthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseasesGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesImaging in pancreatic disease.Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.A comparison of three (67/68)Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelatorA modeling analysis of the effects of molecular size and binding affinity on tumor targeting.68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogueDosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.Dosimetry of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human - repeated scanning in human is possibleSynthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes.A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity.Efficient (18)F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta CellsDevelopment of a new thiol site-specific prosthetic group and its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas.Sphingomyelin patches on pancreatic beta-cells are indicative of insulin secretory capacity.Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.Targets and probes for non-invasive imaging of β-cells.Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Radiometallated peptides for molecular imaging and targeted therapy.Radiopharmaceutical development of radiolabelled peptides.¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.Pancreatic β-cell imaging in humans: fiction or option?Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.Radiolabeled peptides: valuable tools for the detection and treatment of cancerGlucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?Non-invasive monitoring of pancreatic tumor progression in the RIP1-Tag2 mouse by magnetic resonance imaging.
P2860
Q26766690-294C3B2B-BF9D-45BF-AB2B-76CCD6999EAAQ27025187-65CC54F5-C32B-4EDE-9EEC-E11CE53371B8Q28067465-71883E5F-08B3-4727-812C-B6CD9272069EQ30275458-77740CF1-D912-45F9-8FB9-77E0B931497DQ30364628-D7699FB1-0C45-49AD-B44E-D35DA4F6FEBAQ30379845-37249BC2-FCA6-4356-A5E0-695086B8E392Q33833281-CA4D6DDB-E958-46AC-8133-AD5B43C424A1Q33835328-D4444585-6A53-4617-934C-7BB5C69356D9Q33915233-7F8C0A2A-CE25-4C8B-80E6-67484D7E8CC4Q34579936-E5AB1D78-326A-434A-8513-FDD88CF065E8Q35087846-396EB022-1FC7-40DF-ACDB-6CA7E1F9E7ABQ35256800-04CEF7C5-C7E5-4E15-925D-122DE6EC4790Q35402008-0BF9986F-B9B5-4E20-AC5A-476E09746DA6Q35656591-B9F7F3D3-78B5-4640-8B9D-CAC456091B93Q35794797-3F311D70-DCFB-4FDD-AEAD-8A974E8F1D1FQ36383709-632B7EAF-665B-42E5-B67B-277FA945055EQ36742916-7D9A7DB0-3059-4461-A571-0D9C1DFADD77Q36903400-D1B029E8-0DEC-4E5F-95AB-5A6C0A764BC7Q37116075-348D0264-4A67-4065-9B62-EFFC2D7B90A7Q37134464-B26766F4-11C5-4A47-8E5D-4659081EC320Q37188818-7DE83992-25CC-42F6-809A-113EEFC01D9CQ37343392-3A45D120-60F1-4C13-84E6-6976B5DB4A07Q37607383-A4805077-B60C-4999-91FB-1A4201D549BDQ37662672-7C496C31-0D72-40CA-9CDF-418DFD5F2A88Q37731335-492E7C06-F8E6-4853-BF10-52EE1E89615BQ37847064-0199FC25-F2FE-4DE4-AE68-095AFA792621Q37990399-2ADCA13D-D356-4501-8938-582560F21E26Q37990403-8B0E4526-4DAE-4191-8847-E50518300F7BQ38558006-CFAB7809-3481-44D6-9552-EBA8AE2B5544Q38850036-8F454502-2E72-4D02-A6FB-711EBB54EA0EQ39596344-4E8A756A-20D7-4795-B507-FAB8C175FF5AQ42392588-BCED450D-88F4-4CAC-89F5-D18AF86268D1Q42692487-4DA2CEAF-8C8C-4A50-B3D5-9961D235F727Q46618702-7534D6E2-1AC9-4143-97D2-51BC07776ED3
P2860
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
[Lys40
@nl
[Lys40(Ahx-DTPA-111In)NH2]-Exe ...... rgeted therapy for insulinoma.
@en
type
label
[Lys40
@nl
[Lys40(Ahx-DTPA-111In)NH2]-Exe ...... rgeted therapy for insulinoma.
@en
prefLabel
[Lys40
@nl
[Lys40(Ahx-DTPA-111In)NH2]-Exe ...... rgeted therapy for insulinoma.
@en
P2093
P1476
[Lys40(Ahx-DTPA-111In)NH2]-Exe ...... rgeted therapy for insulinoma.
@en
P2093
Christian Seemayer
Damian Wild
Daniel Storch
Gerhard Christofori
Helmut R Mäcke
Jean-Claude Reubi
Martin Behe
Martin Gotthardt
Michael J Mihatsch
Stefan Kneifel
P304
P356
10.1158/1078-0432.CCR-06-2965
P407
P577
2007-06-01T00:00:00Z